Articles tagged with Metastasis
Researchers have direct evidence that epithelial-to-mesenchymal transition (EMT) occurs in human ovarian cancer patients, resulting in unique characteristics and resistance to chemotherapy. This finding highlights the need for combination therapy targeting both primary tumors and metastatic cells.
Researchers at UCLA's Jonsson Comprehensive Cancer Center have successfully combined cellular therapy and gene therapy in a mouse-model system to develop a viable treatment strategy for breast cancer that has spread to the brain. The approach shows significant promise in reducing metastatic brain tumor size, providing new hope for pati...
A new therapeutic approach to treating prostate cancer has been identified through a study on the FoxM1 protein. Depletion of FoxM1 in prostate epithelial cells inhibits tumor cell proliferation, metastasis, and new blood vessel formation.
Researchers discovered a biological mechanism that preserves intestinal tracts in mice treated with lethal doses of chemotherapy, increasing survival rates by up to 75%. The findings could revolutionize cancer therapy by allowing humans to tolerate stronger doses of chemotherapy and radiation, potentially curing later-stage metastasize...
Researchers at Saint Louis University found that high-dose interleukin-2 (HD IL-2) therapy can improve the life span of melanoma patients with brain metastases. The study, published in Chemotherapy Research and Practice, reviewed cases of eight patients who underwent this treatment.
Researchers develop method to filter out cancer cells from cerebrospinal fluid to prevent brain metastasis and decrease complications. This technique may help treat breast cancer and other metastasizing cancers earlier and with potentially fewer drugs.
Scientists have identified a novel gene, mda-9/syntenin, as a potential therapeutic target for bladder cancer. The study showed that the gene helps regulate bladder cancer growth and metastasis, making it a promising target for detecting and monitoring the disease.
Researchers have discovered that cancer cells can fuse with blood cells, enabling them to travel through the body and seed new tumors. This breakthrough has major implications for treating metastatic cancers.
Researchers found that consuming soy peptide lunasin orally reduced the number of metastatic tumors in mice with human colon cancer cells. The highest dose of 20 mg/kg of lunasin achieved a 94% reduction in tumors, showing promise for new cancer treatment approaches.
Removing MerTK from immune cells decreases tumor growth and metastasis in breast, melanoma, and colon cancers. Inhibition of MerTK may stimulate anti-tumor responses and have clinical benefits.
Researchers from Max Planck Institute discovered the P2Y2 receptor molecule on blood platelet walls enables tumor cells to enter organs via blood vessel openings. Blocking this key molecule may lead to new therapeutic approaches for malignant tumors.
Researchers have identified microRNA-22 as a driver of both cancer onset and metastasis, particularly in breast cancer and blood cancers. The study suggests that inhibiting miR-22 through a 'decoy' method could offer a novel therapeutic option for treating these diseases.
Researchers at Yale University found that a human metastatic tumor can arise when a leukocyte and a cancer cell fuse to form a genetic hybrid, potentially explaining how cancer cells travel to distant organs. The study's findings provide the first evidence of such a phenomenon in humans and could lead to new therapy targets.
A new study by RI-MUHC researchers identifies a previously unknown mode of cancer progression, where infection-fighting white blood cells activate cancer cells and facilitate their spread to secondary tumours. Medications already used for other non-cancer diseases may prevent this mechanism of cancer spread or metastasis.
Researchers found that PET-CT improved staging accuracy and intrathoracic disease identification in limited-stage small-cell lung cancer patients. This led to an improvement in overall survival rates compared to those not staged with PET-CT.
A study by University of Notre Dame researchers found that cancer cells use antioxidant enzymes to survive detachment from the extracellular matrix. This discovery may lead to targeted therapies for metastatic cancers.
Researchers found that a developmental protein called ROR1 promotes cancer metastasis by regulating epithelial-mesenchymal transition. Silencing ROR1 reverses this process and inhibits tumor growth in animal models.
A subgroup analysis from a phase III clinical trial found that eribulin demonstrated a greater potential benefit in overall survival compared to capecitabine for women with previously treated metastatic breast cancer. Specifically, patients with multiple organs involved, those who had not received chemotherapy for six months or longer,...
Researchers at Uni Basel have discovered Sox4 as a key player in cancer metastasis, triggering the epithelial-mesenchymal transition (EMT) process. The study found that Sox4 promotes the expression of genes involved in EMT and metastasis, leading to changes in gene expression and cell behavior.
A new hybrid molecular imaging system combines positron emission tomography and magnetic resonance to detect recurrent prostate cancer. The study reveals that PET/MR finds more areas of metastases than PET/CT, making it a viable alternative for restaging patients with metastatic prostate cancer.
Researchers have developed a novel imaging agent, Tc-99m MIP-1404, which binds to PSMA enzyme in prostate cancer cells, enabling detection of metastases. The agent shows promise in detecting lesions more accurately than standard bone imaging.
Researchers at University of South Florida found a combination of nontoxic therapies prolonged survival time by 78% in mice with metastatic cancer. The treatment combined ketogenic diet and hyperbaric oxygen therapy, both non-toxic to healthy tissues while damaging cancer cells.
Scientists developed a potential new drug that destroys cancer cells while preventing their spread to other sites in the body. The compound was tested in laboratory mice and showed promising results.
The EORTC BOS 2 trial aims to improve outcomes for patients with resectable liver metastases from colorectal cancer by testing the efficacy of bevacizumab or panitumumab added to standard peri-operative FOLFOX 4 chemotherapy. The trial plans to accrue 360 patients in 50 sites across ten countries.
Researchers at Berkeley Lab identified the microenvironment surrounding microvasculature as a niche where dormant breast tumor cells reside. The study reveals that stable microvasculature suppresses growth and creates a dormant niche, while sprouting neovasculature sparks micrometastatic outgrowth.
A genetic rogue element known as chimeric transcript LCT13 is linked to the silencing of a tumor suppressor gene TFPI-2, promoting cancer invasion and metastasis. The study suggests that 'junk DNA' can interfere with normal cell function, providing new insights into cancer progression.
Researchers have discovered that targeting regulatory T cells can help eliminate cancer cells, while a new fluorescence labeling method enables the visualization of microRNAs in tissue sections. Additionally, studies suggest that malnourishment exacerbates Giardia infection in mice, leading to severe gastrointestinal problems and growt...
Researchers have identified a five-amino acid fragment of prosaposin that significantly reduces metastatic spread in mouse models of prostate, breast and lung cancer. The findings suggest a potential new approach to blocking metastasis in various cancers.
Researchers at MU College of Veterinary Medicine have created radioactive nanoparticles that target lymphoma tumor cells, a crucial step toward treating metastasized cancers. The nanoparticles, made with lutetium and gold shells, can deliver radiation to tumors without harming healthy cells.
Researchers found that a tumor-activated protein, VEGF-C, activates integrin α4β1 on lymphatic vessels in lymph node tissues, making them more attractive to metastatic tumor cells. This highlights the way tumors can have long-range effects on other parts of the body, impacting tumor metastasis or growth.
Researchers at Stanford University School of Medicine developed a new technique to visualize cell interactions in living mice, pinpointing metastatic cancer cells' locations after breaking off from initial tumor sites. The method uses light-emitting proteins and has potential applications in studying various cell interactions.
A recent study by Henry Ford Health reveals that prostate cancer patients with metastasis are more likely to die after weekend emergency department visits compared to weekdays. The study found that these patients have a 23% increased likelihood of death after weekend visits, despite being older and healthier on average.
Researchers have discovered that breast cancer patients with dense breasts are more likely to develop aggressive tumors. A protein called DDR2 plays a key role in this process, facilitating the spread of cancer cells by activating a multistep pathway.
Scientists at Weill Cornell Medicine have discovered two key proteins that work to block cancer's spread by generating a microenvironment that prevents cancer cells from settling and growing in distant organs. The study suggests that therapeutic proteins could offer a new treatment strategy for metastatic cancer.
Cancer cells exhibit unique physical properties as they metastasize, including increased deformability and reduced oxygen consumption. This study provides new insights into the dynamics of cancer cell behavior, suggesting that these traits enable them to spread through the body.
Researchers have developed a new way to learn how good cells go bad by studying the mechanical and biochemical behavior of cells simultaneously. This technology combines atomic force microscopy and nuclear magnetic resonance, allowing for detailed insights into disease processes.
Researchers discovered metastasis stem cells in the blood of breast cancer patients, characterized by specific surface molecules CD44, CD47, and MET. These cells are associated with a poorer prognosis and may serve as a promising biomarker for disease progression.
Research finds that palliative radiotherapy significantly improves the quality of life for elderly patients with painful bone metastases. The treatment, which involves a single fraction of radiotherapy, has been shown to be effective in all age groups, including those over 75, despite some variability in response.
A new therapy uses radioactive Listeria bacteria to selectively infect tumor cells and deliver radioisotopes, dramatically decreasing the number of metastases in a mouse model of highly aggressive pancreatic cancer. The treatment also showed promise in reducing metastases by 90% in mice with metastatic pancreatic cancer.
Dr. Susan E. Clare's research aims to deliver chemotherapy directly to brain metastases using immune cells and nanoparticles, targeting HER2 positive and triple negative breast cancers. The system uses nanoshells coated with gold to release drugs at will in the appropriate spot in the brain.
Researchers found that combining CT imaging findings with baseline serum lactate dehydrogenase levels can accurately predict patient survival. Patients with low baseline serum LDH and evidence of tumor devascularization on their initial post-therapy CT scans are likely to have a favorable response to therapy.
High levels of kisspeptins in aggressive breast cancers increase tumor grade and metastatic potential, according to Western University research. The study suggests that estrogen receptor status may play a role in kisspeptin's unusual behavior, making it a potential diagnostic biomarker for more aggressive breast cancer.
Researchers found that HIF1 and HIF2 are overexpressed in melanoma tumors, promoting the spread of cancer through the lymphatic system. Suppressing these transcription factors reduced the rate of metastasis in mouse models.
LSUHSC researchers identify LKB1 and Nischarin as a functional duo that regulate breast cancer cell migration and tumor growth. The study provides insight into the molecular mechanisms of tumor suppressor genes.
A team of researchers at Baylor College of Medicine has identified a signature of biomarkers that identifies circulating breast tumor cells destined to seed the brain with deadly cancer. The study shows limitations of current platforms used to identify cancer in this way, but also offers new hope for diagnosis and treatment.
Research at the University of Colorado Anschutz Medical Campus reveals that hsa-miR-146a is overexpressed in most metastatic bladder cancer tumors. This tiny miRNA molecule plays a crucial role in making bladder cancer more aggressive.
Research reveals Six2 homeoprotein promotes detachment of breast cancer cells from tissues, enabling their survival through the bloodstream and colonization at distant sites. Higher Six2 expression in human breast cancer tissues is associated with aggressive metastasis.
A novel protein governing metastasis and chemoresistance in pediatric osteosarcoma has been discovered using K9 osteosarcoma samples. The IGF2BP1 protein's overexpression is linked to aggressive disease progression, offering a potential target for treatment.
A Phase III clinical trial found that adding cetuximab to chemotherapy enables previously inoperable patients to undergo surgery, tripling the rates of successful surgery for liver metastasis. The combination also extends median overall survival by 10 months compared to chemotherapy alone.
Researchers have developed a non-invasive test for metastatic prostate cancer using whole-genome analysis of plasma DNA, which identifies abnormal copy numbers of specific sequences. This breakthrough could aid personalized therapy and target treatment for castration-resistant prostate cancer.
Researchers at Moffitt Cancer Center found that microRNA-155 overexpression promotes new blood vessel growth, tumor inflammation, and metastasis in breast cancer. Controlling miR-155 expression could inhibit malignant growth, providing a new avenue of treatment.
The CTC-iChip system rapidly produces a purified solution of tumor cells for pathological and molecular analysis. This technology enables the analysis of single metastatic cells, providing insights into cancer evolution and metastasis.
A CU Cancer Center study reveals that the transcription factor SPDEF regulates E-Cadherin production, inhibiting prostate cancer metastasis. The researchers found that increasing or decreasing SPDEF levels directly affects E-Cadherin expression, making it a crucial factor in preventing cancer spread.
Researchers at Sanford-Burnham Medical Research Institute discovered that the enzyme PKCζ acts as a tumor suppressor in both mice and humans, controlling cell growth and metastasis. Restoring PKCζ levels may provide a novel therapeutic target for treating prostate cancer.
Researchers at UNC have found that protein palladin enhances cancer-associated fibroblasts' ability to break down barriers and create pathways for tumors to spread. This discovery could lead to new treatments and screening options for pancreatic cancers.
Researchers have developed a multi-stage, multi-orifice flow fractionation system to detect and separate circulating tumor cells (CTCs) from blood with high efficiency, improving separation efficiency to 98.9%. The device, called MS-MOFF, employs hydrodynamic sorting and can collect viable CTCs after sorting.
A study by the ZEUS group found no significant difference in the incidence of bone metastases between patients receiving zoledronic acid and those on standard treatment. The 50-month study suggested that zoledronic acid may not be effective in preventing hormone therapy-induced bone loss in high-risk prostate cancer patients.
A large multicentre study found that small kidney tumours can have an aggressive potential and should be treated. The study included 2197 patients with RCC of 4 cm or smaller and showed that the risk of nodal disease or distant metastasis increased significantly with rising tumour diameter.
A study published in Science Signaling identified a critical protein role in the spread of melanoma to the lungs. Researchers found that inhibiting the adenosine diphosphate ribosylation factor 6 (ARF6) protein reduces melanoma metastasis.
Researchers at VCU Massey Cancer Center have developed a novel immunotherapy that could work like a vaccine against metastatic cancers. The therapy, called Flagrp-170, uses a molecule engineered to stimulate the immune system and attack cancer cells, with promising results in animal models.